Dendreon Corp fka DNDNQ

[rancherho]

walldiver:

Your post brings to mind the fact that DNDN stated that it is supposed to submit data on all Provenge treated patients as part of its safety data package. I wonder if this is just the safety data amassed during the period of various trials, or whether it has solicited follow-up long-term data through its clinical investigators for all Provenge trials to date. The 5 year post 9901 randomization point is coming up, with the 4 year point having already been passed for 9902a. The info on remaining survivors of the 28 9901 and 21 9902a 36 month survivors could be very instructive as to how durable the three dose course of Provenge therapy is, especially if long term survivors were willing to have their PAP reactive memory T cell levels checked.

Good luck to all DNDN longs.